

Psilocybin as a Possible Interruption of Entrenched Brain States

ABSURD HEALTH INSTITUTE | 15 OCTOBER 2026 | VI. Psychedelic state medicine and the biology of joy

Abstract

This concept paper examines psilocybin as a possible interruption of entrenched brain states. It develops an argument drawn from Psychedelic Terrain Medicine, identifies the relevant biological or clinical mechanisms, and considers where that argument may fail. This is a narrative perspective, not a systematic review or an original clinical study.

The central problem

Psilocybin is being investigated for psychiatric disorders under carefully controlled conditions. The source book interprets psychedelic experience as a possible interruption of entrenched fear, rumination and self-referential patterns. The clinical question is whether durable functional change follows, for whom, and through which combination of pharmacology, psychological support, experience and integration. The language of “reset” is metaphorical unless defined through reproducible measurements.

Mechanisms and causal architecture

Psilocybin acts principally through serotonergic mechanisms, particularly 5-HT_{2A} receptor engagement, and is associated with marked changes in perception and experience. Network-level changes and altered self-processing are under investigation, but no single brain scan establishes therapeutic mechanism. The Goodwin phase 2 trial in treatment-resistant depression found greater short-term improvement with a 25-mg condition compared with a 1-mg comparator at three weeks, alongside adverse effects; durable benefit and generalizability require further evidence. Therapeutic context complicates blinding and causal attribution because participants may recognize active psychedelic effects.

A discriminating example

In a clinical trial, a dramatic psychedelic experience is not the same as verified remission. The psychological support, expectations, acute perceptual effects and selection of participants all influence interpretation. A mechanism paper should ask what persists after the event and what measures of daily function change, not simply whether the experience was powerful.

Competing explanations and limitations

Psychiatric risks include distressing experiences, destabilization, mania or psychosis vulnerability, and impaired judgment during intoxication. Study populations typically screen out some high-risk participants, so trial results cannot be generalized to every patient. A compelling subjective sense of rebirth is not equivalent to proven neurological repair. Moreover, current regulatory and legal status varies by jurisdiction and setting.

What evidence would change the interpretation?

Better evidence would distinguish pharmacological effects from expectations and psychosocial support, use appropriate comparators, track durable symptom and functional outcomes, and report adverse experiences in all groups. Neurological imaging should be linked to prospective functional change rather than interpreted as proof of therapeutic mechanism by itself.

Implications for medical interpretation

The paper's contribution is a serious, cautious articulation of the state-interruption hypothesis. It does not recommend unsupervised use or replace established treatments for depression or other disorders.

Selected scientific reading

Goodwin et al. (2022), Single-dose psilocybin for a treatment-resistant episode of major depression, New England Journal of Medicine.

<https://doi.org/10.1056/NEJMoa2206443>

McEwen (1998), Protective and damaging effects of stress mediators, New England Journal of Medicine.

<https://doi.org/10.1056/NEJM199801153380307>

Original source: Psychedelic Terrain Medicine. All source books supplied by the author.

Conceptual research commentary. Not a peer-reviewed clinical study, original trial, systematic review, validated diagnostic instrument or treatment protocol. Consult qualified care for medical decisions.